Skip to main content
SpringerLink
Log in

Cost Effectiveness of Pharmacotherapy for the Prevention of Migraine

A Markov Model Application

  • Original Research Article
  • Published:
CNS Drugs Aims and scope Submit manuscript

Abstract

Background: There are few data about the cost effectiveness of prophylactic medications for migraine. Clinical trials have shown several preventive agents to be useful in reducing the frequency of migraine attack while having tolerable side effects.

Objective: To compare the cost effectiveness of adding preventive treatment to abortive therapy for acute migraine with abortive therapy for acute migraine alone in the primary care setting.

Methods: A Markov decision analytic model with a cycle length of 1 day, a time horizon of 365 days and three health states was used to perform an analysis comparing the cost effectiveness and utility of five treatments for migraine prophylaxis (amitriptyline 75 mg/day, topiramate 100 and 200 mg/day, timolol 20 mg/day, divalproex sodium 1000 mg/day or propranolol 160 mg/day) with treatment of acute migraine alone for the management of migraine in the primary care setting. One-way and probabilistic sensitivity analyses were performed to test the robustness of the results.

Results: The expected total annual cost for the use of preventive agents ranged from $US2932 to $US3887, compared with $US3960 for the use of abortive medications only. In the baseline analysis, use of each of the five preventive agents generated more quality-adjusted life-years (QALYs) and incurred lower costs compared with abortive medications only. Monte Carlo Simulation suggested that amitriptyline 75 mg/day was most likely to be considered a cost-effective option versus the other five therapies, followed by timolol 20 mg/day, topiramate 200 mg/day, topiramate 100 mg/day, divalproex sodium 1000 mg/day and propranolol 160 mg/day when the willingness-to-pay (WTP) for society is <$US18 000 per QALY gained.

Conclusions: Preventive medications appear to be a cost-effective approach to the management of migraine in the primary care setting compared with the approach of abortive treatment only. Among those preventive agents, probabilistic sensitivity analysis suggests that, when the societal WTP is <$US18 000 per QALY gained, amitriptyline 75mg/day is most likely to be considered a cost-effective option.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Table I
Table II
Table III
Table IV
Fig. 2
Table V
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Morey V, Rothrock JF. Examining the utility of in-clinic “rescue” therapy for acute migraine. Headache 2008; 48(6): 939–43

    Article  PubMed  Google Scholar 

  2. Lipton RB, Diamond S, Reed M, et al. Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache 2001; 41(7): 646–57

    Article  PubMed  CAS  Google Scholar 

  3. Brown JS, Papadopoulos G, Neumann PJ, et al. Cost-effectiveness of topiramate in migraine prevention: results from a pharmacoeconomic model of topiramate treatment. Headache 2005; 45(8): 1012–22

    Article  PubMed  Google Scholar 

  4. Adelman JU, Adelman LC, von Seggern R. Cost-effectiveness of antiepileptic drugs in migraine prophylaxis. Headache 2002; 42(10): 978–83

    Article  PubMed  Google Scholar 

  5. Farmer K, Cady R, Bleiberg J, et al. Sumatriptan nasal spray and cognitive function during migraine: results of an open-label study. Headache 2001; 41(4): 377–84

    Article  PubMed  CAS  Google Scholar 

  6. Rapoport AM. Pharmacological prevention of migraine. Clin Neurosci 1998; 5(1): 55–9

    PubMed  CAS  Google Scholar 

  7. Bland S. Migraine prophylaxis. J Pharm Soc Wis 2000 Nov/Dec; 20-4

  8. Demaagd G. The pharmacological management of migraine: part 2. Preventive therapy [online]. PT 2008; 33(8): 480–7. Available from URL: http://www.ptcommunity.com/ptjournal/fulltext/33/8/PTJ3308480.pdf [Accessed 2010 Feb 23]

    Google Scholar 

  9. Ramadan NM, Silberstein SD, Freitag FG, et al. Evidence-based guidelines for migraine headache in the primary care setting: pharmacological management for prevention of migraine [online]. Available from URL: http://www.aan.com/professionals/practice/pdfs/gl0090.pdf [Accessed 2010 Apr 26]

  10. Silberstein SD, Goadsby PJ. Migraine: preventive treatment. Cephalalgia 2002; 22(7): 491–512

    Article  PubMed  CAS  Google Scholar 

  11. Cole JC, Lin P, Rupnow MF. Validation of the Migraine-Specific Quality of Life Questionnaire version 2.1 (MSQ v. 2.1) for patients undergoing prophylactic migraine treatment. Qual Life Res 2007; 16(7): 1231–7

    Article  Google Scholar 

  12. Rapoport A, Bigal M. Migraine preventive therapy: current and emerging treatment options. Neurol Sci 2005; 26: 111–20

    Article  Google Scholar 

  13. Ramadan NM. Current trends in migraine prophylaxis. Headache 2007; 47 Suppl. 1: S52–7

    Article  PubMed  Google Scholar 

  14. Soto J. Health economic evaluations using decision analytic modeling: principles and practices: utilization of a checklist to their development and appraisal. Int J Technol Assess Health Care 2002; 18(1): 94–111

    PubMed  Google Scholar 

  15. Perfetto EM, Weis KA, Mullins CD, et al. An economic evaluation of triptan products for migraine. Value Health 2005; 8(6): 647–55

    Article  PubMed  Google Scholar 

  16. Zhang L, Hay JW. Cost-effectiveness analysis of rizatriptan and sumatriptan versus cafergot in the acute treatment of migraine. CNS Drugs 2005; 19(7): 635–42

    Article  PubMed  CAS  Google Scholar 

  17. Price MJ, Briggs AH. Development of an economic model to assess the cost effectiveness of asthma management strategies. Pharmacoeconomics 2002; 20(3): 183–94

    Article  PubMed  Google Scholar 

  18. Brown JS, Papadopoulos G, Neumann PJ, et al. Cost-effectiveness of topiramate in migraine prevention: results from a pharmacoeconomic model of topiramate treatment. Headache 2005; 45(8): 1012–22

    Article  PubMed  Google Scholar 

  19. Ferrari MD, Goadsby PJ, Roon KI, et al. Triptans (serotonin, 5-HT1B/1D agonists) in migraine: detailed results and methods of a meta-analysis of 53 trials. Cephalalgia 2002; 22(8): 633–58

    Article  PubMed  CAS  Google Scholar 

  20. Ferrari MD, Roon KI, Lipton RB, et al. Oral triptans (serotonin 5-HT(1B/1D) agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet 2001; 358(9294): 1668–75

    Article  PubMed  CAS  Google Scholar 

  21. Dodick DW, Sandrini G, Williams P. Use of the sustained pain-free plus no adverse events endpoint in clinical trials of triptans in acute migraine. CNS Drugs 2007; 21(1): 73–82

    Article  PubMed  CAS  Google Scholar 

  22. Hu XH, Markson LE, Lipton RB, et al. Burden of migraine in the United States: disability and economic costs. Arch Intern Med 1999; 159(8): 813–8

    Article  PubMed  CAS  Google Scholar 

  23. Brown JS, Neumann PJ, Papadopoulos G, et al. Migraine frequency and health utilities: findings from a multisite survey. Value Health 2008; 11(2): 315–21

    Article  PubMed  Google Scholar 

  24. Brandes JL, Saper JR, Diamond M, et al. Topiramate for migraine prevention: a randomized controlled trial. JAMA 2004; 291(8): 965–73

    Article  PubMed  CAS  Google Scholar 

  25. Briggs A, Sculpher M. An introduction to Markov modelling for economic evaluation. Pharmacoeconomics 1998; 13(4): 397–409

    Article  PubMed  CAS  Google Scholar 

  26. Maizels M, Houle T. Results of screening with the brief headache screen compared with a modified IDMigraine. Headache 2008; 48(3): 385–94

    Article  PubMed  Google Scholar 

  27. Lipton RB, Bigal ME, Diamond M, et al. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology 2007; 68(5): 343–9

    Article  PubMed  CAS  Google Scholar 

  28. Ferrari MD. The economic burden of migraine to society. Pharmacoeconomics 1998; 13(6): 667–76

    Article  PubMed  CAS  Google Scholar 

  29. Gallagher RM, Kunkel R. Migraine medication attributes important for patient compliance: concerns about side effects may delay treatment. Headache 2003; 43(1): 36–43

    Article  PubMed  Google Scholar 

  30. Lipton RB, Diamond S, Reed M, et al. Migraine diagnosis and treatment: results from the American Migraine Study II. Headache 2001; 41(7): 638–45

    Article  PubMed  CAS  Google Scholar 

  31. Stewart WF, Lipton RB. Prevalence of migraine headache in the United States [abstract]. JAMA 1992; 267(1): 64

    Article  PubMed  CAS  Google Scholar 

  32. Mathew NT. The prophylactic treatment of chronic daily headache. Headache 2006; 46(10): 1552–64

    Article  PubMed  Google Scholar 

  33. Linde K, Rossnagel K. Propranolol for migraine prophylaxis. Cochrane Database Syst Rev 2004; (2): CD003225

  34. Tfelt-Hansen P, Block G, Dahlöf C, et al. Guidelines for controlled trials of drugs in migraine: second edition. Cephalalgia 2000; 20(9): 765–86

    Article  PubMed  CAS  Google Scholar 

  35. Diener HC, Matias-Guiu J, Hartung E, et al. Efficacy and tolerability in migraine prophylaxis of flunarizine in reduced doses: a comparison with propranolol 160 mg daily. Cephalalgia 2002; 22(3): 209–21

    Article  PubMed  CAS  Google Scholar 

  36. Diener HC, Bussone G, Van Oene JC, et al. Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study. Cephalalgia 2007; 27(7): 814–23

    Article  PubMed  Google Scholar 

  37. Silberstein SD, Neto W, Schmitt J, et al. Topiramate in migraine prevention: results of a large controlled trial. Arch Neurol 2004; 61(4): 490–5

    Article  PubMed  Google Scholar 

  38. Keskinbora K, Aydinli I. A double-blind randomized controlled trial of topiramate and amitriptyline either alone or in combination for the prevention of migraine. Clin Neurol Neurosurg 2008; 110(10): 979–84

    Article  PubMed  Google Scholar 

  39. Peres MF, Silberstein S, Moreira F, et al. Patients’ preference for migraine preventive therapy. Headache 2007; 47(4): 540–5

    Article  PubMed  Google Scholar 

  40. Bulut S, Berilgen MS, Baran A, et al. Venlafaxine versus amitriptyline in the prophylactic treatment of migraine: randomized, double-blind, crossover study. Clin Neurol Neurosurg 2004; 107(1): 44–8

    Article  PubMed  Google Scholar 

  41. Bendtsen L, Jensen R, Olesen J. Amitriptyline, a combined serotonin and noradrenaline re-uptake inhibitor, reduces exteroceptive suppression of temporal muscle activity in patients with chronic tension-type headache. Electro-encephalogr Clin Neurophysiol 1996; 101(5): 418–22

    CAS  Google Scholar 

  42. Keskinbora K, Aydinli I. A double-blind randomized controlled trial of topiramate and amitriptyline either alone or in combination for the prevention of migraine. Clin Neurol Neurosurg 2008; 110(10): 979–84

    Article  PubMed  Google Scholar 

  43. Carroll JD, Reidy M, Savundra PA, et al. Long-acting propranolol in the prophylaxis of migraine: a comparative study of two doses. Cephalalgia 1990; 10(2): 101–5

    Article  PubMed  CAS  Google Scholar 

  44. Diener HC, Tfelt-Hansen P, Dahlof C, et al. Topiramate in migraine prophylaxis: results from a placebo-controlled trial with propranolol as an active control. J Neurol 2004; 251(8): 943–50

    Article  PubMed  CAS  Google Scholar 

  45. Tfelt-Hansen P, Standnes B, Kangasneimi P, et al. Timolol versus propranolol versus placebo in common migraine prophylaxis: a double-blind multicenter trial. Acta Neurol Scand 1984; 69(1): 1–8

    Article  PubMed  CAS  Google Scholar 

  46. Pradalier A, Serratrice G, Collard M, et al. Long-acting propranolol in migraine prophylaxis: results of a double-blind, placebo-controlled study. Cephalalgia 1989; 9(4): 247–53

    PubMed  CAS  Google Scholar 

  47. Stellar S, Ahrens SP, Meibohm AR, et al. Migraine prevention with timolol: a double-blind crossover study. JAMA 1984; 252(18): 2576–80

    Article  PubMed  CAS  Google Scholar 

  48. Freitag FG, Collins SD, Carlson HA, et al. A randomized trial of divalproex sodium extended-release tablets in migraine prophylaxis. Neurology 2002; 58(11): 1652–9

    Article  PubMed  CAS  Google Scholar 

  49. Klapper J. Divalproex sodium in migraine prophylaxis: a dose-controlled study. Cephalalgia 1997; 17(2): 103–8

    Article  PubMed  CAS  Google Scholar 

  50. Dodick DW, Freitag F, Banks J, et al. Topiramate versus amitriptyline in migraine prevention: a 26-week, multi-center, randomized, double-blind, double-dummy, parallel-group noninferiority trial in adult migraineurs. Clin Ther 2009; 31(3): 542–59

    Article  PubMed  CAS  Google Scholar 

  51. Storey JR, Calder CS, Hart DE, et al. Topiramate in migraine prevention: a double-blind, placebo-controlled study. Headache 2001; 41(10): 968–75

    Article  PubMed  CAS  Google Scholar 

  52. Millan-Guerrero RO, Isais-Millan R, Barreto-Vizcaino S, et al. Subcutaneous histamine versus topiramate in migraine prophylaxis: a double-blind study. Eur Neurol 2008; 59(5): 237–42

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

No sources of funding were used to conduct this study. The authors have no conflicts of interest that are directly relevant to the content of this study.

Author information

Authors and Affiliations

  1. University of Utah Pharmacotherapy Outcomes Research Center, 30 South 2000 East, Salt Lake City, Utah, 84112, USA

    Junhua Yu &  Diana I. Brixner

  2. Section of Decision Sciences and Clinical Systems Modeling, School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA

    Kenneth J. Smith

Authors
  1. Junhua Yu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kenneth J. Smith
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Diana I. Brixner
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Diana I. Brixner.

Appendix

Appendix

See table AI for efficacy and adverse effects measure for prophylactic medications for migraine.

Table AI
figure Tab6

Table AI

Full size image

Rights and permissions

Reprints and permissions

About this article

Cite this article

Yu, J., Smith, K.J. & Brixner, D.I. Cost Effectiveness of Pharmacotherapy for the Prevention of Migraine. CNS Drugs 24, 695–712 (2010). https://doi.org/10.2165/11531180-000000000-00000

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/11531180-000000000-00000

Keywords

Search

Navigation